Archives
Liposome Co-Delivery of Cisplatin and Procainamide: Enhanced
2026-05-13
Liposome Co-Delivery of Cisplatin and Procainamide: Enhanced Antiproliferative Effects
Study Background and Research Question
Cisplatin (cis-diamminedichloroplatinum(II), DDP) is a widely used chemotherapeutic agent, but its clinical application is limited by dose-dependent nephrotoxicity and hepatotoxicity. Procainamide hydrochloride, primarily known as a cardiac sodium channel blocker, has recently attracted attention for its ancillary anti-inflammatory and epigenetic-modulating properties, including inhibition of DNA methyltransferase 1 (DNMT1). Prior reports suggested that procainamide hydrochloride can both protect against cisplatin-induced tissue toxicity and potentiate cisplatin’s antitumor activity, but the optimal method for co-delivery and the mechanistic basis of this synergy remained incompletely defined (paper). The present study investigates whether encapsulating both cisplatin and procainamide hydrochloride in multilamellar liposomes can enhance antiproliferative effects against tumor cell lines, while potentially reducing the toxicity traditionally associated with free cisplatin administration.Key Innovation from the Reference Study
The central innovation lies in the co-encapsulation of two mechanistically distinct agents—cisplatin and procainamide hydrochloride—within the same liposomal delivery vehicle. This approach leverages procainamide’s ability to modulate both cellular electrophysiology and epigenetic states, hypothesizing that it may not only reduce cisplatin toxicity but also increase its cytotoxic efficiency against cancer cells. The study further distinguishes between drugs present in bulk solution and those embedded within the liposome’s internal aqueous compartments, enabling a nuanced analysis of delivery context and drug synergy (paper).Methods and Experimental Design Insights
Multilamellar liposomes were prepared by the hydration of a lipid film, followed by encapsulation of cisplatin and procainamide hydrochloride, either individually or in combination. Both filtered and unfiltered formulations were produced to assess the contribution of drugs in bulk solution versus those sequestered within the liposomal core. Physicochemical characterization included measurements of mean diameter (327 ± 3 nm for DDP-liposomes; 465 ± 5 nm for DDP/PA-liposomes) and polydispersity index (0.3 ± 0.1 for both), ensuring acceptable size distribution for cell-based assays (paper). Drug loading was quantified spectrophotometrically, revealing higher procainamide incorporation (3.1 ± 0.3 × 10−4 M) in co-loaded liposomes, likely due to the cationic nature of procainamide and its electrostatic interactions with negatively charged liposomal surfaces. The antiproliferative activities of these formulations were assessed via MTT assay in three human cancer cell lines: ovarian carcinoma (A2780), lung carcinoma (A549), and non-Hodgkin lymphoma (DOHH2). Comparative efficacy was determined for free drugs, single-agent liposomes, and combination-loaded liposomes.Protocol Parameters
- assay | MTT cell viability | cell lines: A549, A2780, DOHH2 | standard for antiproliferative activity quantification | paper
- cisplatin concentration (solution) | 1–16 μM | dose-response in A549 | benchmark for comparison with liposomal forms | paper
- cisplatin in liposomes | 0.312–5 μM | improved delivery/efficacy profile | reflects sustained release and uptake | paper
- procainamide concentration (co-loaded liposomes) | 3.1 × 10−4 M | maximized by cationic interaction | supports co-delivery strategy | paper
- liposome size | 327–465 nm | ensures cellular uptake | widely used for drug delivery | paper
- procainamide solubility in DMSO | ≥13.65 mg/mL | for stock solutions in workflow | allows flexibility in assay setup | product_spec
- procainamide storage | -20°C | maintains stability | standard for solid compounds | product_spec
Core Findings and Why They Matter
The study found that procainamide hydrochloride alone did not exert significant antiproliferative activity at concentrations up to 160 μM (cell viability remained above 96% in A549 cells), confirming its low direct cytotoxicity in this context. However, when combined with cisplatin—either as a mixture in solution or, more importantly, co-loaded within liposomes—procainamide potentiated cisplatin’s antiproliferative effect, particularly in A549 lung carcinoma cells (paper). The IC50 for cisplatin in solution was 4.46 ± 0.58 μM, whereas liposomal cisplatin demonstrated greater potency with an IC50 of 2.23 ± 0.17 μM. This efficacy was further enhanced in combination liposomes, where procainamide’s presence did not diminish, and often increased, the cytotoxic effect of cisplatin. Mechanistically, the observed synergy may arise from procainamide’s known ability to inhibit DNMT1 and modulate DNA methylation, sensitizing cancer cells to DNA-damaging agents (internal). Importantly, procainamide also mitigated cisplatin-induced nephrotoxicity and hepatotoxicity in vivo, with evidence that this protective effect can be achieved without compromising antitumor efficacy—even in sensitive settings such as pregnancy (internal). The formation of a less toxic coordination complex between DDP and procainamide is proposed to underlie this chemoprotective property.Comparison with Existing Internal Articles
Recent internal articles reinforce the multifaceted role of procainamide hydrochloride:- Synergistic Antiproliferative Effects of Cisplatin and Procainamide Liposomes independently confirms that co-encapsulation enhances efficacy and provides mechanistic rationale for combinatorial liposomal delivery in oncology.
- Procainamide Hydrochloride: A Mechanistic Bridge from Cardiac to Epigenetic Research highlights the dual impact of procainamide as both a cardiac sodium channel blocker and DNA methylation regulator, supporting the translational potential observed in the reference study.
- Procainamide Hydrochloride: Chemoprotection in Cisplatin-Treated Pregnancy provides in vivo evidence for procainamide’s protective effect on maternal and embryonic outcomes during cisplatin therapy, echoing the reduced toxicity profile suggested in the liposome-based approach.
Limitations and Transferability
While the enhanced antiproliferative effect of co-loaded liposomes is robust in vitro, several limitations warrant careful consideration:- In vivo validation of synergistic efficacy and chemoprotection is pending for the specific liposomal formulations used. Prior animal studies with free drugs provide supportive, but not conclusive, evidence (internal).
- Findings are cell line-specific; transferability to primary tumor models or heterogeneous clinical samples remains to be established.
- The mechanistic interplay between procainamide’s cardiac ion channel modulation and epigenetic effects in the context of tumor biology needs further exploration.
- Liposomal preparation methods may impact drug loading ratios and reproducibility, which are critical for protocol translation to other systems (paper).